1-3 of 3
Mike Dennis
Close
Sort by
Journal Articles

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Clinical Trials & Observations
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, Steve Knapper, Sylvie D. Freeman, Leona M. Batten, Joanna Canham, Emily L. Hinson, Julie Wych, Sophie Betteridge, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4539–4549.
https://doi.org/10.1182/bloodadvances.2023010276
Published: 2023
Includes: Supplemental data
Journal Articles

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients

Mike Dennis, Ian F. Thomas, Cono Ariti, Laura Upton, Alan K. Burnett, Amanda Gilkes, Rohini Radia, Claire Hemmaway, Priyanka Mehta, Steven Knapper, Richard E. Clark, Mhairi Copland, Nigel Russell, Robert K. Hills
Journal: Blood Advances
Blood Adv (2021) 5 (24): 5621–5625.
https://doi.org/10.1182/bloodadvances.2021005038
Published: 2021
Includes: Supplemental data
Journal Articles

Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML

Clinical Trials & Observations
Giuseppe Visani, Federica Loscocco, Mike Dennis, Eliana Zuffa, Anna Candoni, Alberto Sensi, Barbara Giannini, Gerardo Musuraca, Anna Maria Mianulli, Marino Clavio, Marco Rocchi, Davide Gibellini, Mohsen Navari, Amanda Gilkes, Pier Paolo Piccaluga, Alessandro Isidori
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5040–5049.
https://doi.org/10.1182/bloodadvances.2020002305
Published: 2020
Includes: Supplemental data